About Shield therapeutics plc
Shield Therapeutics Plc: A Specialty Pharmaceutical Company Focused on Hospital-Focused Pharmaceuticals
Shield Therapeutics Plc is a specialty pharmaceutical company that is dedicated to the development and commercialization of late-stage, hospital-focused pharmaceuticals. The company was founded in 2008 and has its headquarters in Gateshead, United Kingdom. Shield Therapeutics is committed to improving the lives of patients by developing innovative treatments for unmet medical needs.
The company's primary focus is on iron deficiency, which affects millions of people worldwide. Iron deficiency can lead to anemia, fatigue, and other serious health problems. Shield Therapeutics has developed a novel oral iron replacement therapy called Feraccru® (ferric maltol), which has been approved for use in Europe and the UK.
Feraccru® is a unique formulation that delivers iron directly to the site where it's needed most – the small intestine – without causing gastrointestinal side effects such as nausea or constipation. This makes it an ideal treatment option for patients who cannot tolerate traditional oral iron supplements.
In addition to Feraccru®, Shield Therapeutics has several other products in its pipeline that are focused on addressing unmet medical needs in hospital settings. These include PT20 (a novel hepcidin mimetic) for the treatment of anemia associated with chronic kidney disease and ST10 (a novel phosphate binder) for hyperphosphatemia associated with chronic kidney disease.
Shield Therapeutics' commitment to innovation extends beyond product development. The company also invests heavily in research and development activities aimed at advancing our understanding of iron metabolism and related diseases.
One example of this commitment is Shield's participation in HEART-FID (Heart Failure Iron Deficiency), a large-scale clinical trial investigating whether treating iron deficiency can improve outcomes for heart failure patients. This study aims to provide important insights into how best to manage this common comorbidity among heart failure patients.
Another example is Shield's collaboration with the University of Oxford to develop a novel diagnostic test for iron deficiency. This test will help clinicians identify patients who are at risk of developing iron deficiency and enable earlier intervention.
Shield Therapeutics is also committed to building strong partnerships with healthcare providers, patient advocacy groups, and other stakeholders in the healthcare ecosystem. The company works closely with these groups to ensure that its products meet the needs of patients and are accessible to those who need them most.
In conclusion, Shield Therapeutics Plc is a specialty pharmaceutical company that is dedicated to improving the lives of patients by developing innovative treatments for unmet medical needs. With its focus on iron deficiency and other hospital-focused conditions, Shield Therapeutics is well-positioned to make a significant impact on patient outcomes. Through its commitment to innovation, research, and collaboration, Shield Therapeutics is poised for continued success in the years ahead.
shieldtherapeutics.com
